Related references
Note: Only part of the references are listed.Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future
Jeffrey Cummings et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches
Julia R. Clarke et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
Pierrick Bourgeat et al.
NEUROIMAGE (2018)
Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials
Abdelrahman Ibrahim Abushouk et al.
BMC NEUROLOGY (2017)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
Steve Balsis et al.
CLINICAL NEUROPSYCHOLOGIST (2015)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Instrumental variable methods for causal inference
Michael Baiocchi et al.
STATISTICS IN MEDICINE (2014)
Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease
Lars Lannfelt et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?
Kevin Mullane et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
Bruno P. Imbimbo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
Peter T. Nelson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Resolving controversies on the path to Alzheimer's therapeutics
Dennis J. Selkoe
NATURE MEDICINE (2011)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Eric Karran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
PET imaging of amyloid deposition in patients with mild cognitive impairment
Anton Forsberg et al.
NEUROBIOLOGY OF AGING (2008)
Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline
J Näslund et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)